APTN
ADAPTIN BIO, INC.—
Filing reports
2
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 1/2
Price
Daily candles with volume.
No data for this timeframe.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
SecBot reports
2 filings · 0 bullish · 0 bearish · 2 neutral- NEUTRAL EFFECTSep 10, 2026
The SEC declared effective Adaptin Bio's S-1 registration statement (File No. 333-298622) on…
The effectiveness removes the final regulatory hurdle for selling stockholders to trade shares. Monitor for any subsequent Form 4 filings indicating insider sales, which could create near-term…
- NEUTRAL S-1Aug 28, 2026
Adaptin Bio filed an S-1 registration statement to register 382,400 shares of common stock and…
The resale registration is small relative to float and does not represent a primary offering. Monitor for any clinical data readouts from the APTN-101 Phase I trial and for the company's ability to…
All APTN filing & press-release reports (2)
- EFFECT reportSep 10, 2026
- S-1 reportAug 28, 2026